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Objectives: Time to 12-week confirmed disability progression, measured by the 
Expanded Disability Status Scale (EDSS), is a key endpoint in RRMS trials. However, 
the EDSS has widely discussed limitations, and several therapies have shown 
inconsistent results for this endpoint in terms of statistical significance. Here 
we contextualize differences in 12-week confirmed disability progression results 
in the Phase 3 studies of gastro-resistant dimethyl fumarate (DMF), DEFINE and 
CONFIRM. MethOds: Time to 12-week confirmed disability progression at 2 years 
was a secondary endpoint in both studies; however, the studies were not powered 
to detect statistical significance for this endpoint. Patients had the option of dis-
continuing study treatment and initiating alternative therapy at any time due to 
12-week confirmed disability progression or after completing 48 weeks of study 
treatment and experiencing one confirmed relapse after 24 weeks (DEFINE) or two 
confirmed relapses at any time (CONFIRM). Results: Although gastro-resistant 
DMF 240mg BID demonstrated consistent reductions on 12-week confirmed dis-
ability progression, statistical significance was achieved in DEFINE (p= 0.0050) but 
not CONFIRM (p= 0.2536). There was an apparent difference in the placebo rate 
of 12-week confirmed disability progression at 2 years (DEFINE, 27%; CONFIRM, 
17%). In CONFIRM, a relatively higher percentage of placebo patients (4.1%) versus 
gastro-resistant DMF patients (1.7%) switched to alternative MS therapy or with-
drew after the time of tentative disability progression without a subsequent EDSS 
assessment. Additionally, a relatively higher percentage of placebo patients who 
switched to alternative MS therapy had ≥ 2 relapses without 12-week confirmed 
disability progression prior to switch in CONFIRM (45%) compared with DEFINE 
(16%). cOnclusiOns: Relapse-based criteria for switching to alternative therapy 
may have contributed to the lower placebo progression rate and decreased assay 
sensitivity for this particular endpoint in CONFIRM. The totality of evidence needs 
to be taken into account when assessing a therapy’s effect on disability progression.
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Objectives: To examine annual prevalence and treatment rates of multiple 
sclerosis (MS) patients using a large US commercial administrative claims data-
base. MethOds: Random sample of 5 million lives from the IMS LifeLink Plus 
database was used for this analysis. Individuals with ≥ 1 month eligibility were 
included in the denominator; those with ≥ 1 month eligibility and an MS diagnosis 
(ICD-9-CM: 340. xx) were included in the numerator. Presence of a disease-modifying 
drug (DMD) was defined as ≥ 1 claim during the calendar year of interest. Baseline 
demographics and clinical characteristics were evaluated for each group. Annual 
prevalence (per 10,000) and treatment rates were reported for each calendar year 
(2006–2012) and were further stratified by age and gender. Results: MS patients 
were older than patients without MS (mean age range 46.8–47.7 vs. 34.4-35.1, respec-
tively) and more likely to be female (73% vs. 51%, respectively). Comorbidities such as 
gastrointestinal disorders (42.8%), hypertension (43.5%), arthritis (24.8%) and anxiety 
(22.8%) were common among MS patients (2006 estimates). MS prevalence ranged 
from 16.4/10,000 (2006) to 17.8/10,000 (2010). Similar patterns over the years were 
observed when data were stratified by sex and age, with absolute rates being higher 
among women vs. men (24.4/10,000 vs. 8.2/10,000, respectively; 2012; P< 0.001) and 
patients aged 45–64 years (29.4/10,000 vs. 0.4/, 15.6/ and 18.2/10,000 patients aged 
< 18, 18–44 and ≥ 65, respectively; P< 0.001). The proportion of MS patients receiv-
ing a DMD increased from 2006 (42.5%) to 2012 (51.2%) (P< 0.001). Similar rates and 
trends in the proportion of patients with a DMD were observed when stratified 
by gender (42.8% (2006) and 51.3% (2012) [female]; 41.5% (2006) and 50.7% (2012) 
[male]; both P< 0.001). cOnclusiOns: In a recent 5-year period, MS prevalence 
in a large US insured population increased slightly, with a greater increase in the 
likelihood of DMD use.
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Objectives: Multiple Sclerosis (MS) is a chronic disease of the Central Nerve 
System. The aim of this paper is to characterize the various clinical and demographi-
cal feature of the MS population. MethOds: In a 6-month cross-sectional study248 
patients were investigated in Khorasan provinces. Data was collected by employing 
a 32- item self-administered questionnaire in a face to face interview. Results: 
A total of 248 patients were recruited (186 female, 75%; 62 male, 25%). The mean 
age was 31.9±8.7, the mean onset age was 26.3 (26.3±8: 1) and the median dura-
tion of illness was 3.8 years. The prevalence and incidence were estimated to be 
25/100000 and 2.5/100,000 respectively. Significantly more patients had a Relapsing 
Remitting MS course. Self reported character of MS individuals were significantly 
more (193, 77.8%) regarding nervous character (p value= .000). A family history of 
ms was reported in 11%. However, there was no a significant difference between 
men and women with respect to age, age of onset, BMI, disease duration and gap 
between clinical onset and diagnosis. The education level was reported as 154 (62%) 
had a bachelor and greater degree and 94 (38%) had a diploma or under-diploma 
degree. Thirty six percents of the patients were born in the spring. cOnclusiOns: 
In contrast to reports from Caucasians, the Iranian differs with respect to age, age 
of onset of illness, disease duration, family history, sex ratio. The sex ratio of 3: 1 
in this study is somewhat higher than the usual 2: 1 in the standard text and seen 
in Asia or the neighboring Arab countries. This might reflect the role of hormone 
or genetic factors or much more visiting by women, or women stressful life. These 
included BMI, birth season, education stand. The educated people in developing 
country are probably likely to adopt a “western” lifestyle, therefore more probably 
to get the risk of developing Western disease.
ment of the catheter tip was associated with fewer shunt failures, as demonstrated in 
9 clinical studies investigating accurate catheter placement using the AxiEM™ IGNS 
(Medtronic Inc). In addition to being costly, studies showed shunt revision surgery 
was associated with significant morbidity and lower long-term QOL. In a study of 80 
paediatric Hydrocephalus patients, investigators found that patients with a history 
of two or more shunt revision surgeries had a significantly worse QOL (p< 0.02), as 
measured by the Hydrocephalus Outcomes Questionnaire (HOQ). cOnclusiOns: The 
use of IGNS significantly increases the accuracy of ventricular catheter placement 
compared to freehand techniques in hydrocephalus patients undergoing ventricular 
shunt insertion. Clinical studies have shown the use of IGNS in shunt placement 
surgery results in lower shunt failure rates, which improve QOL and lowers the eco-
nomic impact to payers.
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Objectives: Teriflunomide and dimethyl fumarate (DMF), oral therapies for relaps-
ing–remitting multiple sclerosis (RRMS), have demonstrated efficacy in clinical trials. 
Despite challenges in comparing outcomes across studies, exploratory analyses 
of treatment effects can be compared informally using relative reductions in a 
specific endpoint. However, these outcomes do not account for differences in dis-
ease severity among study populations or differences on very low event rates. The 
number needed to treat (NNT) to prevent an event is an important outcome to 
consider for any comparisons within the field of MS. MethOds: NNTs were derived 
using data from studies with teriflunomide 14 mg (TEMSO, NCT00134563; TOWER, 
NCT00751881) or DMF (DEFINE, NCT00420212; CONFIRM, NCT00451451) based on 
inverse of absolute differences between treatment and placebo groups. Results: 
Teriflunomide studies included patients with progressive disease; patients in 
DEFINE had slightly lower Expanded Disability Status Scale scores. Teriflunomide 
and DMF significantly reduced risk of relapse (all studies). NNTs to prevent one 
relapse were similar across studies (5.9 [TEMSO], 5.6 [TOWER], 5.3 [DEFINE], 5.6 
[CONFIRM]). Risk of disability progression sustained for 12 weeks was significantly 
reduced in TEMSO, TOWER, and DEFINE but not CONFIRM. Corresponding NNTs to 
prevent disability progression were 13.8, 17.4, 10.8, and 30.2. Risk of relapse leading 
to hospitalization was significantly reduced in TEMSO and TOWER but not in DEFINE 
and CONFIRM. Corresponding NNTs were lower in TEMSO (12.5) and TOWER (20) 
than in DEFINE (50) and CONFIRM (50). cOnclusiOns: Using the NNT approach, we 
demonstrate a comparable effect size for teriflunomide and DMF on relapse. NNTs 
to prevent disability progression with teriflunomide showed a consistent signifi-
cant reduction in risk versus placebo in both TEMSO and TOWER, whereas for DMF, 
comparable NNTs were observed only in DEFINE, and not in CONFIRM. Reduction 
of risk for relapse leading to hospitalization was significant only for teriflunomide.
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Objectives: Alzheimer’s Disease (AD) destroys brain cells, causing problems 
with memory, thinking, and behavior severe enough to affect work, family and 
social relationships, and basic activities of daily living. AD gets worse over time, 
it is incurable and fatal. Donepezil, galantamine, rivastigmine and memantine 
are the current treatment options but the latest evidence was not systematically 
reviewed recently. MethOds: PubMed, Health Technology Assessment Database, 
NHS Economic Evaluation Database, Cochrane Central Register of Controlled 
Trials, Cochrane Database of Systematic Reviews, DAHTA-Datenbank, PSYNDEX 
and PsycINFOwere searched systematically for randomized-controlled studies. 
For the abstracts that met the pre-defined inclusion criteria, full text articles were 
obtained. The abstracts that did not meet the search criteria were excluded. Based 
on these manuscripts it was evaluated whether each study meets the selection cri-
teria. Results: After elimination of duplicates the search indicated above yielded 
418 articles of which another 299 were excluded based on the title selection; after 
abstract review, 82 articles have been reviewed in full text which were also deemed 
to be relevant based on the research question. For donepezil 24 RCTs were available 
for which another 4 subgroup and exploratory analyses have been published. For 
galantamine 11 RCTs with 6 exploratory analysis are available. For rivastigmine 10 
RCTs are available with 7 exploratory papers. For memantine 14 RCTs with 6 explora-
tory analysis were found. Out of those studies eleven head-to-head studies are avail-
able; 5 studies comparing donepezil vs memantine, 3 studies comparing donepezil vs 
rivastigmine and one study each comparing donepezil vs galatamine, rivastagmine 
vs memantine. There was one study comparing rivastagmine vs donepezil vs galan-
tamine. In comparison the clinical evidence seems diverse dependent on the patient 
characteristics, study duration, and severity of disease. cOnclusiOns: Appropriate 
evidence assessment for the approved AD treatments requires clinical expertise and 
close review of the study characteristics.
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